Treatment of esophagogastric junction carcinoma: An unsolved debate

Abstract

The incidence of esophagogastric junction adenocarcinoma (AEG) is increasing worldwide. Barrett's esophagus (BE) associated with dysplasia is the main risk factor for the development of cancer. Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. Several endoscopic approaches are here discussed. Surgical strategies for different types of AEG cancer are now fairly standardized, and multidisciplinary strategies using chemotherapy or chemoradiotherapy may improve the outcome of these patients. Here we briefly discuss the keypoints, main topics, and critical issues, according to accumulating evidence and taking into account our own experience.

Malnutrition status and related factors in gastric cancer patients undergoing chemotherapy treatment at Ho Chi Minh City oncology hospital

“…2 Chemotherapy is a systemic therapy that can improve outcome of resectable gastric cancer with extended lymph node dissection. 3 Gastric cancer survival rates have been increasing steadily due to better detection methods, more effective adjuvant therapies; palliative chemotherapy had demonstrated to prolong survival without compromising the quality of life in metastatic gastric cancer. But, the most common chemotherapy side effects associated with the gastrointestinal tract are taste changes, chemotherapy-induced nausea and vomiting, constipation, and diarrhea that affect the nutritional status of patients.…”

Gross tumor volume of adenocarcinoma of esophagogastric junction corresponding to cT and cN stages measured with computed tomography to quantitatively determine resectabiliy: A case control study

“…Adenocarcinoma of the esophagogastric junction (AEG) is one of the most common cancers in the world, with an estimated 1 million deaths each year (1)(2)(3). In 1998, Siewert classified AEG into three types, including type I with the tumor center 1-5 cm above the esophagogastric junction, type II with the tumor center located between 1 cm above and 2 cm below the junction, and type III with the tumor center 2-5 cm below the junction.…”

“…In 1998, Siewert classified AEG into three types, including type I with the tumor center 1–5 cm above the esophagogastric junction, type II with the tumor center located between 1 cm above and 2 cm below the junction, and type III with the tumor center 2–5 cm below the junction. This classification has been adopted by the International Gastric Cancer Society and by the International Society for Disease of the Esophagus, and helped clarify that different approaches are needed for the different types of cancer ( 2 , 4 ).…”

Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy

“…Many surgeons resect these tumors by oesophagectomy as for Type I, while others do perform total gastrectomy with resection of the distal oesophagus as for Type III. Literature does not provide definitive evidence of which strategy should be favored [8][9][10][11][12][13][14][15][16][17][18][19][20].…”